Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.
Oppitz has over 30 years’ pharmaceutical and healthcare experience and was most recently a member of the executive committee of BSN Medical in charge of its Latin America business.
In previous capacities, he has led organisations as head of Latin America at Takeda as well as in country management roles at Roche and Aventis Pharma.
He said: “I am excited to join Sobi and I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital speciality care business unit.”
The new role will see Oppitz work with corporate development and the regional and country organisations.
Guido Oelkers, president and CEO of Sobi, said: “We are delighted that Norbert could join Sobi, he is a true entrepreneur and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our speciality care business.”
Source: PMLive
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
